跳至主要内容
临床试验/NCT02557061
NCT02557061已完成不适用

Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers

University Hospital, Rouen2 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2009年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
56
试验地点
2
主要终点
Number of patients with tumor infiltrate by T-lymphocytes (CD3+)

研究概览

简要总结

Colorectal cancer (CRC) is one of the most common cancers in France (36,000 new cases / year) and nearly 16,000 people die each year from this disease. The lymph node involvement of the surgical specimen is today the main tool on which is based the adjuvant treatment decision after curative surgical resection. The study of new predictive factors to identify patients at risk for developing a local or metastatic recurrence is therefore a major challenge.

It is now clear that the immune system plays a role in the control of tumor's development, and it was shown that there was a correlation between the presence of a CD3+ T-lymphocyte infiltrate in colorectal cancers and patient survival. Preliminary studies suggest an important role of regulatory T-lymphocyte in the modulation of the antitumor immune response. The aim of our study is to follow a cohort of patients operated for colon cancer with curative intent to highlight the prognostic characteristics of the tumoral infiltrate by various lymphocyte populations (particularly T-lymphocytes but also B-lymphocytes and regulatory lymphocytes). It will be performed a preoperative analysis of blood circulating lymphocytes with antibodies specific for different cell populations (CD3, CD4, CD8, CD56, CD16, CD19, CD2) and stage of activation (CD25, CD69, HLA-DR ) or differentiation (CD24, CD38, CD27, CD103, CD62L, CCR7, CD45RA / RO, IgD). The presence of regulatory T-lymphocytes will also be analyzed. It will be performed on tumor sample a Tissue Microarrays for immunohistochemical study to determine the presence of different lymphocyte populations. We systematically study the markers CD68 (monocytes / macrophages), CD56 (NK cells), CD20 and CD79a (B cells / plasma cells), CD3 (T cells), CD8 (cytotoxic T), CD4 (helper T) FoxP3 (regulatory T), cytotoxicity of CD8 markers (Fas ligand, perforin and granzyme) and MHC I (antigen presentation) to explore the innate and adaptive immune responses. For each section, the different zones will be analyzed (center and invasive margin and healthy tissue). The main objective of the study is the influence of the tumor infiltration rate by CD3 + T cells on disease free survival at 2-years in patients with non-metastatic colon cancer resection. The secondary objective is to search a correlation between the rate of T-lymphocytes on preoperative blood sample and on tumor sample.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is male or female, and > 18 years of age
  • Patients with nonmetastatic colon cancer histologically proven (stage I, II or III).
  • Patients with curative resection (R0).
  • Patient has agreed to participate by giving written informed consent
  • Patient affiliated to the social security system

排除标准

  • Pregnant or without effective contraception and reproductive age.
  • Patients with synchronous metastatic disease at preoperative assessment (including at least an abdominal ultrasound and chest X-ray (or thoraco-abdominopelvic CT).
  • Patient taking immunosuppressive therapy.
  • Patient with lymphoid hematological disease.
  • Patients with rectal cancer defined by tumor accessible to finger and requiring preoperative radiotherapy (except tumor of upper rectum or rectosigmoid or rectal tumor operated without preoperative radiotherapy)
  • Patient under guardianship.
  • Patient misunderstanding spoken and written French.
  • Patient unable to submit to monitoring study for geographical, social or psychological reasons.

研究组 & 干预措施

Patient with colorectal cancer

Experimental

Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer

干预措施: Colorectal surgery (resection) (Procedure)

Patient with colorectal cancer

Experimental

Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer

干预措施: Blood sampling (Biological)

结局指标

主要结局

Number of patients with tumor infiltrate by T-lymphocytes (CD3+)

时间窗: Day 1

Number of alive patients

时间窗: 2 years

次要结局

  • Rate of preoperative blood T-lymphocytes(day 1 before resection)

研究者

发起方
University Hospital, Rouen
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验